Literature DB >> 11943730

Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in situ breast cancers.

Shelley A Gestl1, Mitchell D Green, Debra A Shearer, Elizabeth Frauenhoffer, Thomas R Tephly, Judith Weisz.   

Abstract

Glucuronidation, mediated by UDP-glucuronosyltransferases (UGTs), affects the actions and disposition of diverse endo- and xenobiotics. In the case of catecholestrogens (CEs), glucuronidation is likely to block their oxidation to quinone estrogens that are the putative mediators of CEs' actions as initiators of cancers. The goal of this study was to determine whether UGT2B7, the isoenzyme with a high affinity for 4-hydroxyestrone, is expressed in human breast parenchyma. Glucuronidation of 4-hydroxyestrone has relevance to breast carcinogenesis because quinone metabolites of 4-hydroxylated CEs can form potentially mutagenic depurinating DNA adducts, and because in breast tissue estrone is likely to be the predominant estrogen available for 4-hydroxylation. Using reverse transcriptase-polymerase chain reaction, immunocytochemistry, immunoblot analyses, and assays of glucuronidation of 4-hydroxyestrone, we show that UGT2B7 is expressed in human mammary epithelium, and that its expression is dramatically reduced in invasive breast cancers. In many in situ carcinomas, however, 4-hydroxyestrone immunostaining was not only preserved but even more intense than in normal mammary epithelium. The finding of reduced UGT2B7 protein and glucuronidation of 4-hydroxyestrone in invasive cancers suggests a tumor-suppressor function for the enzyme. Recent identification of all-trans retinoic acid as a substrate of UGT2B7 suggests that this function includes the generation of retinoyl-beta-glucuronide, a potent mediator of actions of retinoids important for maintaining epithelia in a differentiated state. Current knowledge does not provide any ready explanation for the apparent increase in UGT2B7 expression in carcinomas in situ. However, this finding, together with reduced immunostaining at loci showing breach of the basement membrane (microinvasion), suggests involvement of UGT2B7-catalyzed reaction(s) in protection against invasion of surrounding tissue by cancer cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11943730      PMCID: PMC1867225          DOI: 10.1016/S0002-9440(10)62572-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  48 in total

Review 1.  Pathology of preinvasive and excellent-prognosis breast cancer.

Authors:  D L Page; J F Simpson
Journal:  Curr Opin Oncol       Date:  2000-11       Impact factor: 3.645

Review 2.  Estrogen metabolism by conjugation.

Authors:  R Raftogianis; C Creveling; R Weinshilboum; J Weisz
Journal:  J Natl Cancer Inst Monogr       Date:  2000

Review 3.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

4.  4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7.

Authors:  V M Samokyszyn; W E Gall; G Zawada; M A Freyaldenhoven; G Chen; P I Mackenzie; T R Tephly; A Radominska-Pandya
Journal:  J Biol Chem       Date:  2000-03-10       Impact factor: 5.157

5.  In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues.

Authors:  L Muskhelishvili; P A Thompson; D F Kusewitt; C Wang; F F Kadlubar
Journal:  J Histochem Cytochem       Date:  2001-02       Impact factor: 2.479

6.  Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine.

Authors:  C P Strassburg; S Kneip; J Topp; P Obermayer-Straub; A Barut; R H Tukey; M P Manns
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

7.  Nuclear localization of catechol-O-methyltransferase in neoplastic and nonneoplastic mammary epithelial cells.

Authors:  J Weisz; G Fritz-Wolz; S Gestl; G A Clawson; C R Creveling; J G Liehr; D Dabbs
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

8.  Cellular localization of uridine diphosphoglucuronosyltransferase 2B enzymes in the human prostate by in situ hybridization and immunohistochemistry.

Authors:  O Barbier; H Lapointe; M El Alfy; D W Hum; A Bélanger
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

Review 9.  Estrogens as endogenous genotoxic agents--DNA adducts and mutations.

Authors:  E Cavalieri; K Frenkel; J G Liehr; E Rogan; D Roy
Journal:  J Natl Cancer Inst Monogr       Date:  2000

10.  Evidence for interference in estradiol-17beta inactivation to estrone by oxidized low-density lipoprotein and selected lipid peroxidation products.

Authors:  W Abplanalp; M Rymaszewski; J Adamski; M T Subbiah
Journal:  J Lab Clin Med       Date:  1999-09
View more
  15 in total

1.  Human UDP-Glucuronosyltransferases: Effects of altered expression in breast and pancreatic cancer cell lines.

Authors:  Centdrika R Dates; Tariq Fahmi; Sebastian J Pyrek; Aiwei Yao-Borengasser; Barbara Borowa-Mazgaj; Stacie M Bratton; Susan A Kadlubar; Peter I Mackenzie; Randy S Haun; Anna Radominska-Pandya
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.

Authors:  Mellissa Yong; Stephen M Schwartz; Charlotte Atkinson; Karen W Makar; Sushma S Thomas; Katherine M Newton; Erin J Aiello Bowles; Victoria L Holt; Wendy M Leisenring; Johanna W Lampe
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02       Impact factor: 4.254

3.  Expression of UDP-glucuronosyltransferase 1A, nuclear factor erythroid-E2-related factor 2 and Kelch-like ECH-associated protein 1 in colonic mucosa, adenoma and adenocarcinoma tissue.

Authors:  Min Wang; Ying-Ying Qi; Shuo Chen; DE-Feng Sun; Shuai Wang; Jian Chen; Yan-Qing Li; Wei Han; Xiao-Yun Yang
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

4.  Circulating estrogen metabolites and risk for breast cancer in premenopausal women.

Authors:  Alan A Arslan; Roy E Shore; Yelena Afanasyeva; Karen L Koenig; Paolo Toniolo; Anne Zeleniuch-Jacquotte
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-08       Impact factor: 4.254

5.  Src supports UDP-glucuronosyltransferase-2B7 detoxification of catechol estrogens associated with breast cancer.

Authors:  Partha S Mitra; Nikhil K Basu; Ida S Owens
Journal:  Biochem Biophys Res Commun       Date:  2009-03-14       Impact factor: 3.575

6.  Meta-analysis of gene expression profiles identifies differential biomarkers for hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Somsak Likhitrattanapisal; Jaitip Tipanee; Tavan Janvilisri
Journal:  Tumour Biol       Date:  2016-07-22

7.  Bisphenol-A glucuronidation in human liver and breast: identification of UDP-glucuronosyltransferases (UGTs) and influence of genetic polymorphisms.

Authors:  Christina M Street; Zhaohui Zhu; Moshe Finel; Michael H Court
Journal:  Xenobiotica       Date:  2016-03-21       Impact factor: 1.908

8.  Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues.

Authors:  Athena Starlard-Davenport; Beverly Lyn-Cook; Anna Radominska-Pandya
Journal:  Steroids       Date:  2008-02-03       Impact factor: 2.668

9.  UGT2B7 is not expressed in normal breast.

Authors:  Chang Sun; Anna Di Rienzo
Journal:  Breast Cancer Res Treat       Date:  2008-12-31       Impact factor: 4.872

10.  The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions.

Authors:  Andrea Y Angstadt; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Junjia Zhu; Carla J Gallagher; Philip Lazarus
Journal:  Genes Chromosomes Cancer       Date:  2014-06       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.